SCHEMBL2649112

SCHEMBL2649112

O=C(O)Cc1ccc(C2CCCCC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.53
S1PR1 P21453 1/20 0.51
S1PR5 Q9H228 1/20 0.51
RORC P51449 1/20 0.50
MITF O75030 1/20 0.50
KLF5 Q13887 1/20 0.50
CA2 P00918 1/20 0.48
CAMK2A Q9UQM7 1/20 0.48
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
HTT P42858 2/20 0.47
ACMSD Q8TDX5 2/20 0.47
KDM4E B2RXH2 1/20 0.47
GLA P06280 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11674678 1.00 HAO1 (0.53) HAO1S1PR1S1PR5RORCMITF
SCHEMBL3289619 0.95 HTT (0.55) HAO1S1PR1S1PR5RORCMITF
SCHEMBL26089356 0.94 CA2 (0.50) HAO1S1PR1S1PR5RORCMITF
SCHEMBL925698 0.90 CA2 (0.54) S1PR1S1PR5CA2CAMK2AHTT
SCHEMBL11478386 0.84 S1PR1 (0.51) HAO1S1PR1S1PR5MITFKLF5
SCHEMBL9751108 0.84 RORC (0.52) HAO1RORCMITFKLF5HTR2C
SCHEMBL7941807 0.84 CA2 (0.50) HAO1RORCCA2HTR2CHTR2B
SCHEMBL1089454 0.83 HAO1 (0.51) HAO1S1PR1S1PR5RORCMITF
SCHEMBL1088973 0.83 HAO1 (0.51) HAO1S1PR1S1PR5RORCMITF
SCHEMBL4651687 0.82 FFAR4 (0.57) HAO1S1PR1S1PR5MITFKLF5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US claimed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US claimed
EP-1833806-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2007-09-19 EP claimed
WO-2006064189-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-06-22 WO claimed
CN-114656363-A Synthetic method of palladium-catalyzed aromatic ester compound 南京林业大学 2022-06-24 CN disclosed
US-20170174840-A1 MOISTURE CURABLE SILICONE COMPOSITION MOMENTIVE PERFORMANCE MATERIALS INC. 2017-06-22 US disclosed
EP-3102325-A1 MOISTURE CURABLE SILICONE COMPOSITION Momentive Performance Materials Inc. (US) 2016-12-14 EP disclosed
WO-2015119904-A1 MOISTURE CURABLE SILICONE COMPOSITION MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2015-08-13 WO disclosed
WO-2014210492-A1 MOISTURE CURABLE COMPOSITION WITH STRONTIUM MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2014-12-31 WO disclosed
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed
EP-0143978-B1 PROCESS FOR MAKING LOW CRYSTALLINITY POLYOLEFINS HERCULES INCORPORATED (US) 1988-03-16 EP disclosed
EP-0108489-B1 METHOD FOR PREPARING AN IMPROVED CATALYST SUPPORT Himont Incorporated (US) 1986-12-10 EP disclosed
US-4540756-A COORDINATION CATALYST OF MAGNESIUM CARBOXYLATE, ORGANOALUMINUM HALIDE, AND GROUP 4B HALIDE HERCULES INCORPORATED (US) 1985-09-10 US disclosed
US-4532313-A Contacting hydrocarbon solutions of magnesium alkanoate and alkylaluminum dichloride in liquid hydrocarbon medium containing alkylaluminum alkanoate chloride HIMONT INCORPORATED (US) 1985-07-30 US disclosed
EP-0032294-B1 SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION Himont Incorporated (US) 1985-05-15 EP disclosed
EP-0108489-A1 Method for preparing an improved catalyst support Himont Incorporated (US) 1984-05-16 EP disclosed
EP-0032294-A2 Solid catalyst component for olefin polymerization Himont Incorporated (US) 1981-07-22 EP disclosed
US-4277372-A TITANIUM CHLORIDE DEPOSITED ON MAGNESIUM CHLORIDE SUPPORT HERCULES INCORPORATED (US) 1981-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 HAO1 1499/4885S1PR1 2815/4885S1PR5 3041/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 HAO1 1599/4885S1PR1 2931/4885S1PR5 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.